Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak
NanoViricides (NYSE:NNVC) has announced the evaluation of its clinical drug NV-387 for treating Measles virus amid a growing outbreak. The drug, which has completed Phase I trials with no adverse events, has shown effectiveness against multiple viruses that use HSPG for infection, including RSV, COVID-19, Influenza, and MPox.
According to CDC data as of April 11, 2025, there are 712 confirmed Measles cases, with 79 hospitalizations (11%) and 3 deaths. The company is open to enabling NV-387's use under FDA's 'Emergency Expanded Access for an Individual Patient' protocols. NanoViricides plans additional laboratory studies to evaluate NV-387's effectiveness against Measles in cell culture and animal models to support a future IND application.
The company argues that vaccination alone may not be sufficient to control outbreaks, citing a 28% vaccine failure rate among hospitalized cases and the need for 95-97% coverage for herd immunity.
NanoViricides (NYSE:NNVC) ha annunciato la valutazione del suo farmaco clinico NV-387 per il trattamento del virus del morbillo in mezzo a un crescente focolaio. Il farmaco, che ha completato la fase I degli studi clinici senza eventi avversi, ha dimostrato efficacia contro diversi virus che utilizzano HSPG per infettare, inclusi RSV, COVID-19, influenza e MPox.
Secondo i dati dei CDC aggiornati all'11 aprile 2025, ci sono 712 casi confermati di morbillo, con 79 ricoveri (11%) e 3 decessi. L'azienda è aperta a consentire l'uso di NV-387 secondo i protocolli di 'Accesso Espanso di Emergenza per un Paziente Individuale' della FDA. NanoViricides prevede ulteriori studi di laboratorio per valutare l'efficacia di NV-387 contro il morbillo in colture cellulari e modelli animali per supportare una futura domanda IND.
L'azienda sostiene che la sola vaccinazione potrebbe non essere sufficiente per controllare i focolai, citando un tasso di fallimento del vaccino del 28% tra i casi ospedalizzati e la necessità di una copertura del 95-97% per l'immunità di gregge.
NanoViricides (NYSE:NNVC) ha anunciado la evaluación de su medicamento clínico NV-387 para tratar el virus del sarampión en medio de un brote creciente. El medicamento, que ha completado ensayos de Fase I sin eventos adversos, ha mostrado eficacia contra múltiples virus que utilizan HSPG para la infección, incluidos RSV, COVID-19, Influenza y MPox.
Según los datos de los CDC al 11 de abril de 2025, hay 712 casos confirmados de sarampión, con 79 hospitalizaciones (11%) y 3 muertes. La empresa está abierta a permitir el uso de NV-387 bajo los protocolos de 'Acceso Ampliado de Emergencia para un Paciente Individual' de la FDA. NanoViricides planea estudios de laboratorio adicionales para evaluar la eficacia de NV-387 contra el sarampión en cultivos celulares y modelos animales para respaldar una futura solicitud IND.
La empresa argumenta que la vacunación por sí sola puede no ser suficiente para controlar los brotes, citando una tasa de fallo de la vacuna del 28% entre los casos hospitalizados y la necesidad de una cobertura del 95-97% para la inmunidad colectiva.
나노바이러스(NYSE:NNVC)는 증가하는 홍역 발병에 대한 치료제로서 임상 약물 NV-387의 평가를 발표했습니다. 이 약물은 부작용 없이 1상 시험을 완료했으며, RSV, COVID-19, 독감 및 MPox를 포함한 여러 바이러스에 대해 HSPG를 사용하여 감염되는 데 효과를 보였습니다.
2025년 4월 11일 기준 CDC 데이터에 따르면 홍역 확진 사례가 712건 있으며, 이 중 79건(11%)이 입원 치료를 받았고 3명이 사망했습니다. 이 회사는 FDA의 '개별 환자를 위한 긴급 확대 접근' 프로토콜에 따라 NV-387의 사용을 허용할 의향이 있습니다. 나노바이러스는 향후 IND 신청을 지원하기 위해 세포 배양 및 동물 모델에서 홍역에 대한 NV-387의 효과를 평가하기 위한 추가 실험실 연구를 계획하고 있습니다.
회사는 단독으로 백신 접종만으로는 발병을 통제하기에 충분하지 않을 수 있다고 주장하며, 입원 사례에서 28%의 백신 실패율과 집단 면역을 위한 95-97%의 면역률이 필요하다고 언급했습니다.
NanoViricides (NYSE:NNVC) a annoncé l'évaluation de son médicament clinique NV-387 pour le traitement du virus de la rougeole au milieu d'une épidémie croissante. Le médicament, qui a terminé les essais de Phase I sans événements indésirables, a montré son efficacité contre plusieurs virus utilisant HSPG pour l'infection, y compris le RSV, le COVID-19, la grippe et le MPox.
Selon les données des CDC au 11 avril 2025, il y a 712 cas confirmés de rougeole, avec 79 hospitalisations (11%) et 3 décès. L'entreprise est ouverte à permettre l'utilisation de NV-387 selon les protocoles de 'Accès Élargi d'Urgence pour un Patient Individuel' de la FDA. NanoViricides prévoit des études de laboratoire supplémentaires pour évaluer l'efficacité de NV-387 contre la rougeole dans des cultures cellulaires et des modèles animaux pour soutenir une future demande IND.
L'entreprise soutient que la vaccination à elle seule peut ne pas suffire à contrôler les épidémies, citant un taux d'échec du vaccin de 28% parmi les cas hospitalisés et la nécessité d'une couverture de 95-97% pour l'immunité collective.
NanoViricides (NYSE:NNVC) hat die Evaluation seines klinischen Medikaments NV-387 zur Behandlung des Masernvirus im Zuge eines wachsenden Ausbruchs angekündigt. Das Medikament hat die Phase-I-Studien ohne unerwünschte Ereignisse abgeschlossen und hat sich als wirksam gegen mehrere Viren erwiesen, die HSPG für die Infektion nutzen, einschließlich RSV, COVID-19, Influenza und MPox.
Nach Angaben der CDC gibt es zum 11. April 2025 712 bestätigte Masernfälle, darunter 79 Hospitalisierungen (11%) und 3 Todesfälle. Das Unternehmen ist offen für die Erlaubnis zur Verwendung von NV-387 unter den 'Notfall-Erweiterten Zugang für einen einzelnen Patienten'-Protokollen der FDA. NanoViricides plant zusätzliche Laborstudien, um die Wirksamkeit von NV-387 gegen Masern in Zellkulturen und Tiermodellen zu bewerten, um einen zukünftigen IND-Antrag zu unterstützen.
Das Unternehmen argumentiert, dass eine Impfung allein möglicherweise nicht ausreicht, um Ausbrüche zu kontrollieren, und verweist auf eine Impfversagerquote von 28% unter hospitalisierten Fällen sowie auf die Notwendigkeit einer Abdeckung von 95-97% für die Herdenimmunität.
- NV-387 completed Phase I trials with no adverse events, showing excellent safety profile
- Company ready to enable emergency access for individual patients under FDA protocols
- NV-387 demonstrated superior effectiveness against multiple viruses (Influenza, COVID-19, RSV, MPox) in animal models
- Additional laboratory studies still needed to evaluate effectiveness against Measles
- No current proof of effectiveness against Measles virus
- IND application for Measles treatment not yet filed
Insights
NanoViricides' announcement represents a strategic positioning of their clinical-stage asset NV-387 to address the ongoing measles outbreak, highlighting a significant unmet medical need. The company makes a compelling scientific case for NV-387's potential effectiveness against measles based on mechanistic similarities with RSV - both viruses utilize heparan sulfate proteoglycan (HSPG) for cellular infection, and NV-387 specifically targets this pathway through decoy-based viral destruction.
The drug's existing safety profile is substantial - it has completed Phase I trials with no reported adverse events and has demonstrated superior efficacy versus approved treatments against four unrelated viruses (Influenza, COVID-19, RSV, and MPox) in animal models. This broad-spectrum activity strengthens the rationale for measles application.
Most significantly, NanoViricides is positioning for immediate real-world use through FDA's "Emergency Expanded Access" pathway, potentially bypassing the typical lengthy development timeline and creating near-term treatment options for hospitalized patients during the current outbreak.
While proper efficacy studies in measles-specific models are still needed for full regulatory approval, the existing safety data and mechanistic rationale could enable compassionate use opportunities. This represents both humanitarian value and commercial validation potential well before traditional approval pathways conclude.
The timing aligns perfectly with CDC data showing 712 confirmed measles cases with treatment options, potentially creating an urgent market opportunity for NV-387 if it demonstrates efficacy.
SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has begun evaluation of its clinical drug NV-387 for the treatment of the Measles virus.
"A drug for measles is at present a completely missing link in the response to measles virus outbreak," said Anil R. Diwan, Ph.D., President & Executive Chairman of the Company, declaring, "Viral spread cannot be contained without an effective drug to minimize illness and stop the virus transmission from the patients."
NanoViricides already has a clinical stage broad-spectrum antiviral drug NV-387 that may be effective for treating Measles infection. NV-387 was found to cure lethal RSV infection in an animal model. Measles virus is related to RSV, and both use the heparan sulfate proteoglycan (HSPG) for infection. NV-387 mimics HSPG, presents itself as a decoy to the virus, and is capable of destroying the virus particle thereby stalling the continuous infection and spread of virus in the body. This provides strong rationale for use of NV-387 to combat Measles virus.
NanoViricides is open to enabling use of NV-387 to combat Measles virus infection in hospitalized patients and welcomes inquiries that are consistent with current FDA regulatory requirements under "Emergency Expanded Access for an Individual Patient" and under "Expanded Access for an Individual Patient".
NV-387 has already completed a Phase I human clinical trial with no reported adverse events, indicating excellent safety and tolerability. Additionally, NV-387 was found to be substantially more effective than approved drugs (where available) against Influenza, COVID-19, RSV, and MPox in relevant animal models. These four unrelated viruses have in common the fact that they all use HSPG for infection.
The Company has planned additional laboratory studies to evaluate the effectiveness of NV-387 against Measles virus infection in cell culture and animal models to support a future IND application, although we believe the results of these studies would not be required for use of NV-387 under FDA regulations pertaining to "Emergency Expanded Access for an Individual Patient".
Measles cases in the USA have continued to rise this year, and the number of jurisdictions has continued to expand. Already, CDC update as of April 11 lists 712 total confirmed cases, but only
The CDC data clearly indicate that surveillance and reporting of Measles cases in 2025 has been much more robust than in 2024[1].
Alarmingly, the CDC data suggest that increased vaccination is unlikely to lead to stopping future outbreaks[2]. Measles is highly communicable, and it is traditionally believed that a vaccine coverage of 95
Thus, without a drug to treat the measles infected patients, the outbreak is unlikely to be tamed readily. This is because the infected persons continue to transmit virus for a very long time, and isolation for such long periods is neither justifiable nor practicable.
"We continue to hear a loud outcry from leading scientists that there is no drug to combat Measles virus," said Anil R. Diwan, Ph.D., President & Executive Chairman of the Company, warning further that "Without a drug, there is no help for the patients, and the virus continues to expand its reach, in spite of increased vaccination campaigns. Without a drug, vaccination alone will not provide a robust response to combat Measles today and in the future."
"The leading scientists should support our efforts at developing NV-387 and enabling a true victory over the Measles virus," Dr. Diwan declared, "rather than merely clamoring about the vaccine."
As discussed in prior press releases, NV-387 is expected to remain an effective treatment even as viruses mutate.
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a publicly traded (NYSE Amer.: NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
[1] In contrast to 2025 as of April 11, CDC reported in 2024 a total of only 285 confirmed cases, but a whopping
[2] This is because the vaccine failure rate stands at about
SOURCE: NanoViricides
View the original press release on ACCESS Newswire
FAQ
What is the effectiveness of NV-387 against Measles virus according to NNVC's latest announcement?
How many Measles cases were reported in 2025 according to the CDC data cited by NNVC?
What is the current status of NV-387's clinical trials for NNVC?
What is the vaccine failure rate for Measles cases in 2025 according to NNVC's analysis?
